Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

573
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
573
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

6.6K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
6.6K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

793
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
793
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

1.9K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.9K
Lipid-derived Compounds in the Human Body01:31

Lipid-derived Compounds in the Human Body

7.3K
Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various  biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
7.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association Between Lipid Profile and COVID-19 Severity: Insights from a Single-Center Cross-Sectional Study in Northern Greece.

Journal of clinical medicine·2025
Same author

Enteral Nutrition Versus a Combination of Enteral and Parenteral Nutrition in Critically Ill Adult Patients in the Intensive Care Unit: An Overview of Systematic Reviews and Meta-Analysis.

Journal of clinical medicine·2025
Same author

Exploring the correlation between triglyceride levels and atherosclerotic cardiovascular disease prevalence in adults with familial hypercholesterolemia: Insights from a cross-sectional analysis in the HELLAS-FH registry.

Journal of clinical lipidology·2025
Same author

Dopamine: A New Player in the Pathogenesis of Diabetic Retinopathy?

International journal of molecular sciences·2024
Same author

A European, Observational, 3-Year Cohort Comparative Study on the Safety of the Fixed Dose Combination Pravastatin 40 mg/Fenofibrate 160 mg vs. Statin Alone in Real Clinical Practice: The POSE Study.

Pharmacoepidemiology and drug safety·2024
Same author

The effect of lipid-lowering treatment on indices of MASLD in familial hypercholesterolemia patients.

Clinical nutrition (Edinburgh, Scotland)·2024

Related Experiment Video

Updated: Mar 23, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Unresolved issues in lipid-lowering treatment.

Konstantinos Tziomalos1

  • 1First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece - ktziomalos@yahoo.com.

Panminerva Medica
|April 2, 2016
PubMed
Summary

Lowering low-density lipoprotein cholesterol (LDL-C) below current targets safely reduces cardiovascular risk, especially for high-risk patients. The role of high-density lipoprotein cholesterol (HDL-C) in atherosclerosis remains uncertain.

More Related Videos

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

1.7K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

Related Experiment Videos

Last Updated: Mar 23, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

1.7K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

Area of Science:

  • Cardiology
  • Lipidology
  • Preventive Medicine

Background:

  • Elevated low-density lipoprotein cholesterol (LDL-C) is a primary modifiable risk factor for cardiovascular disease (CVD).
  • Statins effectively reduce cardiovascular morbidity and mortality in diverse patient populations.
  • Current dyslipidemia management faces unresolved questions regarding optimal LDL-C targets and the role of HDL-C.

Purpose of the Study:

  • To critically evaluate optimal LDL-C levels for cardiovascular risk reduction.
  • To assess the role of high-density lipoprotein cholesterol (HDL-C) in atherosclerosis and its potential as a treatment target.

Main Methods:

  • Review of accumulating data from observational studies.
  • Analysis of interventional studies involving statins and other lipid-lowering agents.
  • Synthesis of evidence regarding LDL-C lowering and HDL-C manipulation in CVD.

Main Results:

  • Considerably lowering LDL-C below current targets is safe and offers further cardiovascular risk reduction, particularly in very high-risk individuals with established CVD.
  • Evidence suggests that HDL-C may not be causally linked to atherosclerosis, and increasing HDL-C levels may not consistently reduce cardiovascular risk.
  • Uncertainty regarding HDL-C's role is amplified in patients achieving very low LDL-C levels with statin therapy.

Conclusions:

  • Aggressive LDL-C lowering is a safe and effective strategy for reducing cardiovascular events, especially in high-risk populations.
  • The clinical benefit of targeting HDL-C remains questionable and requires further investigation.
  • Future research should clarify the independent role of HDL-C in cardiovascular pathogenesis and treatment efficacy.